Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast ...

Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin(R) as a ...

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy ...

Under the terms of the clinical trial collaboration and supply agreement, Coherus Oncology will provide LOQTORZI to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial.

Therapeutic strategies which target immune checkpoint markers and enable the immune system to initiate immune responses against tumor cells represent a major advancement in cancer therapy. The ...

The tumor microenvironment (TME) is highly complex and dynamic, shaped by diverse immune and tumor cell interactions. CD markers and immune checkpoints provide complementary insights into these ...

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies The following represents disclosure ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...